Skin cancer: New markers for better prevention

Pathobiology

Volumn 76, Issue 2, 2009, Pages 64-81

  Greinert, Rüdigger ^a,b  

^a Elbe Kliniken   (Germany)

^b NONE   (Germany)

Author keywords

Biomarker; Epigenetic biomarkers; Gene expression arrays; Molecular epidemiology; Prevention; Skin cancer

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; UVOMORULIN;

BASAL CELL CARCINOMA; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CLINICAL FEATURE; DISEASE PREDISPOSITION; EPIGENETICS; HUMAN; MELANOMA; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SKIN CANCER; SQUAMOUS CELL CARCINOMA; ULTRAVIOLET RADIATION;

CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; EPIDEMIOLOGY, MOLECULAR; HUMANS; INCIDENCE; MELANOMA; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; ULTRAVIOLET RAYS;

EID: 65249139959     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000201675     Document Type: Review

References (174)

1. Jemal A, Ward E, Hao Y, Thun M:Trends in the leading causes of death in the United States, 1970-2002. JAMA 20 05;294:1255-1259.
2. Katalinic A, Kunze U, Schafer T: Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany:incidence, clinical subtypes, tumour stages and localization (epidemiology of sk in cancer). Br J Dermatol 20 03; 149:1200-1206.
3. Diepgen TL, Mahler V: The epidemiology of skin cancer. Br J Dermatol 2002; 146(suppl 61):1-6.
4. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ: Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
5. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-3648.
6. Boyle P, Dore JF, Autier P, Ringborg U: Cancer of the skin:a forgotten problem in Europe. Ann Oncol 2004; 15:5-6.
7. de Vries E, Bray FI, Coebergh JW, Parkin DM:Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. Int J Cancer 2003; 107:119-126.
8. de Vries E, Coebergh JW: Cutaneous malignant melanoma in Europe. Eur J Cancer 2004;40:2355-2366.
9. Pesch B, Ranft U, Jakubis P, Nieuwenhuijsen MJ, Hergemoller A, Unfried K, Jakubis M, Miskovic P, Keegan T: Environmental arsenic exposure from a coal-burning power plant as a potential risk factor for nonmelanoma skin carcinoma:results from a case-control study in the district of Prievidza, Slovakia. Am J Epidemiol 2002; 155:798-809.
10. Nindl I, Gottschling M, Stockfleth E: Human papillomaviruses and non-melanoma skin cancer:basic virology and clinical manifestations. Dis Markers 2007;23:247-259.
11. Armstrong BK, Kricker A:The epidemiology of UV induced skin cancer. J Photochem Photobiol B 2001;63:8-18.
12. Cleaver JE, Crowley E: UV damage, DNA repair and skin carcinogenesis. Front Biosci 2002;7:d1024-d1043.
13. de Gruijl FR, van Kranen HJ, Mullenders LH: UV-induced DNA damage, repair, mutations and oncogenic pathways in skin cancer. J Photochem Photobiol B 2001;63:19-27.
14. Madan V, Hoban P, Strange RC, Fryer AA, Lear JT: Genetics and risk factors for basal cell carcinoma. Br J Dermatol 2006; 154 (suppl 1):5-7.
15. Ramos J, Villa J, Ruiz A, Armstrong R, Matta J:UV dose determines key characteristics of nonmelanoma skin cancer. Cancer Epidemiol Biomarkers Prev 2004; 13:2006-2011.
16. Norval M, Cullen AP, de Gruijl FR, Longstreth J, Takizawa Y, Lucas RM, Noonan FP, van der Leun JC: The effects on human health from stratospheric ozone depletion and its interactions with climate change. Photochem Photobiol Sci 2007;6:232-251.
17. Abdel-Malek ZA, Knittel J, Kadekaro AL, Swope VB, Starner R:The melanocortin 1 receptor and the UV response of human mela-nocytes - a shift in paradigm. Photochem Photobiol 2008;84:501-508.
18. Dulon M, Weichenthal M, Blettner M, Breitbart M, Hetzer M, Greinert R, Baumgardt-Elms C, Breitbart EW: Sun exposure and number of nevi in 5- to 6-year-old European children. J Clin Epidemiol 2002;55:1075-1081.
19. Leiter U, Garbe C: Epidemiology of melanoma and nonmelanoma skin cancer - the role of sunlight. Adv Exp Med Biol 2008;624:89-103.
20. Harrison SL, MacLennan R, Buettner PG: Sun exposure and the incidence of melanocytic nevi in young Australian children. Cancer Epidemiol Biomarkers Prev 2008; 17:2318-2324.
21. Besaratinia A, Pfeifer GP:Sunlight ultraviolet irradiation and BRAF V600 mutagenesis in human melanoma. Hum Mutat 2008;29:983-991.
22. Thomas NE, Edmiston SN, Alexander A, Millikan RC, Groben PA, Hao H, Tolbert D, Berwick M, Busam K, Begg CB, Mattingly D, Ollila DW, Tse CK, Hummer A, Lee-Taylor J, Conway K: Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev 2007; 16:991-997.
23. Daya-Grosjean L, Couve-Privat S: Sonic hedgehog signaling in basal cell carcinomas. Cancer Lett 2005;225:181-192.
24. Xie J: Molecular biology of basal and squamous cell carcinomas. Adv Exp Med Biol 2008;624:241-251.
25. Lupi O: Correlations between the Sonic Hedgehog pathway and basal cell carcinoma. Int J Dermatol 2007; 46: 1113-1117.
26. Benjamin CL, Melnikova VO, Ananthaswamy HN: P53 protein and pathogenesis of melanoma and nonmelanoma skin cancer. Adv Exp Med Biol 2008;624:265-282.
27. Perez-Ordonez B, Beauchemin M, Jordan RC:Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol 2006;59:445-453.
28. Hussein MR:Ultraviolet radiation and skin cancer:molecular mechanisms. J Cutan Pathol 2005;32:191-205.
29. Bosserhoff AK:Novel biomarkers in maligna nt melanoma. Clin Chim Acta 2006;367:28-35.
30. Sekulic A, Haluska P Jr, Miller AJ, Genebriera DL, Ejadi S, Pulido JS, Salomao DR, Thorland EC, Vile RG, Swanson DL, Pockaj BA, Laman SD, Pittelkow MR, Markovic SN: Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc 2008;83:825-846.
31. Dahl C, Guldberg P: The genome and epigenome of malignant melanoma. APMIS 2007; 115:1161-1176.
32. Gerdes MJ, Yuspa SH: The contribution of epidermal stem cells to skin cancer. Stem Cell Rev 2005;1:225-231.
33. Yan X, Owens DM: The skin:a home to multiple classes of epithelial progenitor cells. Stem Cell Rev 2008;4:113-118.
34. Faurschou A, Haedersdal M, Poulsen T, Wulf HC: Squamous cell carcinoma induced by ultraviolet radiation originates from cells of the hair follicle in mice. Exp Dermatol 2007; 16:485-489.
35. Grichnik JM: Melanoma, nevogenesis, and stem cell biology. J Invest Dermatol 2008; 128:2365-2380.
36. Zabierowski SE, Herlyn M:Melanoma stem cells:the dark seed of melanoma. J Clin Oncol 2008;26:2890-2894.
37. Schwabe M, Lubbert M: Epigenetic lesions in malignant melanoma. Curr Pharm Biotechnol 2007;8:382-387.
38. Breitbart EW, Greinert R, Volkmer B: Effectiveness of information campaigns. Prog Biophys Mol Biol 2006;92:167-172.
39. Greinert R, Breitbart EW, Mohar P, Volkmer B:Health initiatives for the prevention of skin cancer. Adv Exp Med Biol 2008;624:125-136.
40. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P, Melchi CF:Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005;41:28-44.
41. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P, Melchi CF: Meta-analysis of risk factors for cutaneous melanoma:II. Sun exposure. Eur J Cancer 2005;41:45-60.
42. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Zanetti R, Masini C, Boyle P, Melchi CF: Meta-analysis of risk factors for cutaneous melanoma:III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005;41:2040-2059.
43. Chen YC, Hunter DJ:Molecular epidemiology of cancer. CA Cancer J Clin 2005;55:45-54.
44. Garbe C, Buttner P, Weiss J, Soyer HP, Stocker U, Kruger S, Roser M, Weckbecker J, Panizzon R, Bahmer F: Associated factors in t he pre va lence of more t han 50 common melanocytic nevi, atypical melanocytic nevi, and actinic lentigines: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. J Invest Dermatol 1994; 102:700-705.
45. Garbe C, Buttner P, Weiss J, Soyer HP, Stocker U, Kruger S, Roser M, Weckbecker J, Panizzon R, Bahmer F: Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk:multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. J Invest Dermatol 1994; 102:695-699.
46. Gallagher R P, McLean DI, Yang CP, Cold-man AJ, Silver HK, Spinelli JJ, Beagrie M: Suntan, sunburn, and pigmentation factors and the frequency of acquired melanocytic nevi in children. Similarities to melanoma: the Vancouver Mole Study. Arch Dermatol 1990;126:770-776.
47. Harrison SL, MacLennan R, Speare R, Wronski I: Sun exposure and melanocytic naevi in young Australian children. Lancet 1994;344:1529-1532.
48. Kelly JW, Rivers JK, MacLennan R, Harrison S, Lewis AE, Tate BJ: Sunlight:a major factor associated with the development of melanocytic nevi in Australian schoolchildren. J Am Acad Dermatol 1994; 30:40-48.
49. Richard MA, Grob JJ, Gouvernet J, Culat J, Normand P, Zarour H, Bonerandi JJ: Role of sun exposure on nevus. First study in age-sex phenotype-controlled populations. Arch Dermatol 1993; 129:1280-1285.
50. Sorahan T, Ball PM, Grimley RP, Pope D: Benign pigmented nevi in children from Kidderminster, England:prevalence and associated factors. J Am Acad Dermatol 1990;22: 747-750.
51. Wiecker TS, Luther H, Buettner P, Bauer J, Garbe C: Moderate sun exposure and nevus counts in parents are associated with development of melanocytic nevi in childhood:a risk factor study in 1,812 kindergarten children. Cancer 2003;97:628-638.
52. Rosenstein BS, Mitchell DL: Action spectra for the induction of pyrimidine(6-4)pyrimi-done photoproducts and cyclobutane pyrimidine dimers in normal human skin fibroblasts. Photochem Photobiol 1987;45: 775-780.
53. Mitchell DL, Brash DE, Nairn RS:Rapid repair kinetics of pyrimidine(6-4)pyrimidone photoproducts in human cells are due to excision rather than conformational change. Nucleic Acids Res 1990;18:963-971.
54. Greinert R, Boguhn O, Harder D, Breitbart EW, Mitchell DL, Volkmer B: The dose dependence of cyclobutane dimer induction and repair in UVB-irradiated human keratinocytes. Photochem Photobiol 2000; 72:701-708.
55. Wang LE, Li C, Strom SS, Goldberg LH, Brewster A, Guo Z, Qiao Y, Clayman GL, Lee JJ, El Naggar AK, Prieto VG, Duvic M, Lippman SM, Weber RS, Kripke ML, Wei Q: Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression. Clin Cancer Res 2007; 13:6532-6539.
56. Wei Q, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Strom SS, Wang LE, Guo Z, Qiao Y, Amos CI, Spitz MR, Duvic M: Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma. J Natl Cancer Inst 2003;95:308-315.
57. Wang LE, Xiong P, Strom SS, Goldberg LH, Lee JE, Ross MI, Mansfield PF, Gershenwald JE, Prieto VG, Cormier JN, Duvic M, Clayman GL, Weber RS, Lippman SM, Amos CI, Spitz MR, Wei Q: In vitro sensitivity to ultraviolet B light and skin cancer risk:a case-control analysis. J Natl Cancer Inst 2005;97: 822-1831.
58. Sage E, Lamolet B, Brulay E, Moustacchi E, Chateauneuf A, Drobetsky EA: Mutagenic specificity of solar UV light in nucleotide excision repair-deficient rodent cells. Proc Natl Acad Sci USA 1996;93:176-180.
59. Dumaz N, Drougard C, Sarasin A, Daya-Grosjean L: Specific UV-induced mutation spectrum in the p53 gene of skin tumors from DNA-repair-deficient xeroderma pig-mentosum patients. Proc Natl Acad Sci USA 1993;90:10529-10533.
60. Nakazawa H, English D, Randell PL, Nakazawa K, Martel N, Armstrong BK, Yamasaki H: UV and skin cancer:specific p53 gene mutation in normal skin as a biologically relevant exposure measurement. Proc Natl Acad Sci USA 1994;91:360-364.
61. Ravanat JL, Douki T, Cadet J:Direct and indirect effects of UV radiation on DNA and its components. J Photochem Photobiol B 2001;63:88-102.
62. Besaratinia A, Kim SI, Pfeifer GP:Rapid repair of UVA-induced oxidized purines and persistence of UVB-induced dipyrimidine lesions determine the mutagenicity of sunlight in mouse cells. FASEB J 2008;22:2379-2392.
63. Runger TM, Kappes UP:Mechanisms of mutation formation with long-wave ultraviolet light (UVA). Photodermatol Photoimmunol Photomed 2008;24:2-10.
64. Ikehata H, Kudo H, Masuda T, Ono T: UVA induces C->T transitions at methyl-CpG-associated dipyrimidine sites in mouse skin epidermis more frequently than UVB. Mutagenesis 2003; 18:511-519.
65. Matsumura Y, Ananthaswamy HN:Molecular mechanisms of photocarcinogenesis. Front Biosci 2002;7:d765-d783.
66. Hussain SP, Hollstein MH, Harris CC: p53 tumor suppressor gene:at the crossroads of molecular carcinogenesis, molecular epidemiology, and human risk assessment. Ann NY Acad Sci 2000;919:79-85.
67. Ziegler A, Leffell DJ, Kunala S, Sharma HW, Gailani M, Simon JA, Halperin AJ, Baden HP, Shapiro PE, Bale AE:Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci USA 1993;90:4216-4220.
68. Brash DE, Ziegler A, Jonason AS, Simon JA, Kunala S, Leffell DJ: Sunlight and sunburn in human skin cancer:p53, apoptosis, and tumor promotion. J Investig Dermatol Symp Proc 1996; 1:136-142.
69. Brash DE: Roles of the transcription factor p53 in keratinocyte carcinomas. Br J Dermatol 2006; 154(suppl 1):8-10.
70. van der Riet P, Karp D, Farmer E, Wei Q, Grossman L, Tokino K, Ruppert JM, Sidransky D:Progression of basal cell carcinoma through loss of chromosome 9q and inactivation of a single p53 allele. Cancer Res 1994; 54:25-27.
71. Nelson MA, Einspahr JG, Alberts DS, Balfour CA, Wymer JA, Welch KL, Salasche SJ, Bangert JL, Grogan TM, Bozzo PO: Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. Cancer Lett 1994;85:23-29.
72. Brash DE: Sunlight and the onset of skin cancer. Trends Genet 1997;13:410-414.
73. Fusenig NE, Boukamp P:Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes. Mol Carcinog 1998;23:144-158.
74. Mitchell DL, Greinert R, de Gruijl FR, Guikers KL, Breitbart EW, Byrom M, Gallmeier MM, Lowery MG, Volkmer B: Effects of chronic low-dose ultraviolet B radiation on DNA damage and repair in mouse skin. Cancer Res 1999;59:2875-2884.
75. Mitchell DL, Volkmer B, Breitbart EW, Byrom M, Lowery MG, Greinert R: Identification of a non-dividing subpopulation of mouse and human epidermal cells exhibiting high levels of persistent ultraviolet photodamage. J Invest Dermatol 2001; 117:590-595.
76. Morris RJ: Keratinocyte stem cells:targets for cutaneous carcinogens. J Clin Invest 2000; 106:3-8.
77. Braun KM, Watt FM:Epidermal label-retaining cells:background and recent applications. J Investig Dermatol Symp Proc 2004; 9:196-201.
78. Watt FM:Epidermal stem cells:markers, patterning and the control of stem cell fate. Philos Trans R Soc Lond B Biol Sci 1998;353: 831-837.
79. Giangreco A, Qin M, Pintar JE, Watt FM: Epidermal stem cells are retained in vivo throughout skin aging. Aging Cell 2008;7: 250-259.
80. Nijhof JG, van Pelt C, Mulder AA, Mitchell DL, Mullenders LH, de Gruijl FR:Epidermal stem and progenitor cells in murine epidermis accumulate UV damage despite NER proficiency. Carcinogenesis 2007; 28:792-800.
81. Quinn AG, Sikkink S, Rees JL:Basal cell carcinomas and squamous cell carcinomas of human skin show distinct patterns of chromosome loss. Cancer Res 1994; 54:4756-4759.
82. Danaee H, Karagas MR, Kelsey KT, Perry AE, Nelson HH:Allelic loss at Drosophila patched gene is highly prevalent in basal and squamous cell carcinomas of the skin. J Invest Dermatol 2006; 126:1152-1158.
83. Healy E, Belgaid CE, Takata M, Vahlquist A, Rehman I, Rigby H, Rees JL: Allelotypes of primary cutaneous melanoma and benign melanocytic nevi. Cancer Res 1996;56:589-593.
84. Park WS, Vortmeyer AO, Pack S, Duray PH, Boni R, Guerami AA, Emmert-Buck MR, Liotta LA, Zhuang Z: Allelic deletion at chromosome 9p21(p16) and 17p13(p53) in micro-dissected sporadic dysplastic nevus. Hum Pathol 1998;29:127-130.
85. Kraemer KH, Patronas NJ, Schiffmann R, Brooks BP, Tamura D, Digiovanna JJ: Xeroderma pigmentosum, trichothiodystrophy and Cockayne syndrome:a complex genotype-phenotype relationship. Neuroscience 2007;145:1388-1396.
86. Hahn H, Wicking C, Zaphiropoulous PG, Gailani MR, Shanley S, Chidambaram A, Vorechovsky I, Holmberg E, Unden AB, Gillies S, Negus K, Smyth I, Pressman C, Leffell DJ, Gerrard B, Goldstein AM, Dean M, Toftgard R, Chenevix-Trench G, Wainwright B, Bale AE: Mutations of the human homolog of Drosophila patched in t he nevoid basal cell carcinoma syndrome. Cell 1996;85:841-851.
87. Gailani MR, Stahle-Backdahl M, Leffell DJ, Glynn M, Zaphiropoulos PG, Pressman C, Unden AB, Dean M, Brash DE, Bale AE, Toftgard R:The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet 1996; 14:78-81.
88. Oro AE, Higgins KM, Hu Z, Bonifas JM, Epstein EH Jr, Scott MP:Basal cell carcinomas in mice overexpressing sonic hedgehog. Science 1997;276:817-821.
89. Kefford RF, Newton Bishop JA, Bergman W, Tucker MA: Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma:a consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999; 17:3245-3251.
90. Chin L, Pomerantz J, DePinho RA:The INK4a/ARF tumor suppressor:one gene-two products - two pathways. Trends Biochem Sci 1998;23:291-296 .
91. Sharpless E, Chin L:The INK4a/ARF locus and melanoma. Oncogene 2003;22:3092-3098.
92. Utikal J, Schadendorf D, Ugurel S:Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies. Arch Dermatol Res 2007;298:469-477.
93. Bosserhoff AK, Hein R, Bogdahn U, Buettner R: Structure and promoter analysis of the gene encoding the human melanoma-inhibiting protein MIA. J Biol Chem 1996;271:490-495.
94. Bosserhoff AK: Melanoma inhibitory activity (MIA): an important molecule in melanoma development and progression. Pigment Cell Res 2005;18:411-416.
95. Poser I, Tatzel J, Kuphal S, Bosserhoff AK: Functional role of MIA in melanocytes and early development of melanoma. Oncogene 2004;23:6115-6124.
96. Vance KW, Goding CR:The transcription network regulating melanocyte development and melanoma. Pigment Cell Res 2004;17:318-325.
97. Wang W, Edington HD, Rao UN, Jukic DM, Land SR, Ferrone S, Kirkwood JM:Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNα2b. Clin Cancer Res 2007; 13:1523-1531.
98. Wang W, Edington HD, Rao UN, Jukic DM, Wang H, Shipe-Spotloe JM, Kirkwood JM: STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNα therapy. J Invest Dermatol 2008; 128:1997-2002.
99. Arumi-Uria M, McNutt NS, Finnerty B: Grading of atypia in nevi: correlation with melanoma risk. Mod Pathol 2003; 16:764-771.
100. Shapiro M, Chren MM, Levy RM, Elder DE, LeBoit PE, Mihm MC Jr, Margolis DJ, Gimotty PA, Ming ME: Variability in nomenclature used for nevi with architectural disorder and cytologic atypia (microscopically dysplastic nevi) by dermatologists and dermatopathologists. J Cutan Pathol 2004; 31:523-530.
101. Elder DE: Precursors to melanoma and their mimics: nevi of special sites. Mod Pathol 2006; 19(suppl 2):S4-S20.
102. Nambiar S, Mirmohammadsadegh A, Doroudi R, Gustrau A, Marini A, Roeder G, Ruzicka T, Hengge UR: Signaling networks in cutaneous melanoma metastasis identified by complementary DNA microarrays. Arch Dermatol 2005; 141:165-173.
103. de Wit NJ, Rijntjes J, Diepstra JH, van Kuppevelt TH, Weidle UH, Ruiter DJ, van Muijen GN:Analysis of differential gene expression in human melanocytic tumour lesions by custom made oligonucleotide arrays. Br J Cancer 2005;92:2249-2261.
104. Dooley TP, Curto EV, Davis RL, Grammatico P, Robinson ES, Wilborn TW: DNA microarrays and likelihood ratio bioinformatic methods:discovery of human melanocyte biomarkers. Pigment Cell Res 2003; 16:245-253.
105. Mirmohammadsadegh A, Baer A, Nambiar S, Bardenheuer W, Hengge UR:Rapid identification of dysregulated genes in cutaneous malignant melanoma metastases using cDNA technology. Cells Tissues Organs 2004; 177:119-123.
106. Seykora JT, Jih D, Elenitsas R, Horng WH, Elder DE: Gene expression profiling of melanocytic lesions. Am J Dermatopathol 2003;25:6-11.
107. Zuidervaart W, van der Velden PA, Hurks MH, van Nieuwpoort FA, Out-Luiting CJ, Singh AD, Frants RR, Jager MJ, Gruis NA: Gene expression profiling identifies tumour markers potentially playing a role in uveal melanoma development. Br J Cancer 2003;89:1914-1919.
108. Hoek KS: DNA microarray analyses of melanoma gene expression:a decade in the mines. Pigment Cell Res 2007;20:466-484.
109. Haqq C, Nosrati M, Sudi lovsky D, Crothers J, Khodabakhsh D, Pulliam BL, Federman S, Miller JR, III, Allen RE, Singer MI, Leong SP, Ljung BM, Sagebiel RW, Kashani-Sabet M:The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA 2005; 102:6092-6097.
110. Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, Lin A, Kluger HM, Berger AJ, Cheng E, Trombetta ES, Wu T, Niinobe M, Yoshikawa K, Hannigan GE, Halaban R: Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 2004;64:5270-5282.
111. Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, Backus J, Atkins D, Wang Y: Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 2005;11:7234-7242.
112. Kaufmann WK, Nevis KR, Qu P, Ibrahim JG, Zhou T, Zhou Y, Simpson DA, Helms-Deaton J, Cordeiro-Stone M, Moore DT, Thomas NE, Hao H, Liu Z, Shields JM, Scott GA, Sharpless NE: Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression. J Invest Dermatol 2008;128:175-187.
113. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J, Bartek J: DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-870.
114. Warters RL, Adamson PJ, Pond CD, Leach-man SA:Melanoma cells express elevated levels of phosphorylated histone H2AX foci. J Invest Dermatol 2005;124:807-817.
115. Itoh T, O'Shea C, Linn S:Impaired regulation of tumor suppressor p53 caused by mutations in the xeroderma pigmentosum DDB2 gene: mutual regulatory interactions between p48(DDB2) and p53. Mol Cell Biol 2003;23:7540-7553.
116. Itoh T, Cado D, Kamide R, Linn S: DDB2 gene disruption leads to skin tumors and resistance to apoptosis after exposure to ultraviolet light but not a chemical carcinogen. Proc Natl Acad Sci USA 2004;101: 2052-2057.
117. Yang G, Zhang G, Pittelkow MR, Ramoni M, Tsao H: Expression profiling of UVB response in melanocytes identifies a set of p53-target genes. J Invest Dermatol 2006; 126:2490-2506.
118. Howell BG, Solish N, Lu C, Watanabe H, Mamelak AJ, Freed I, Wang B, Sauder DN: Microarray profiles of human basal cell carcinoma:insights into tumor growth and behavior. J Dermatol Sci 2005;39:39-51.
119. O'Driscoll L, McMorrow J, Doolan P, Mc-Kiernan E, Mehta JP, Ryan E, Gammell P, Joyce H, O'Donovan N, Walsh N, Clynes M: Investigation of the molecular profile of basal cell carcinoma using whole genome microarrays. Mol Cancer 2006;5:74.
120. Yu M, Zloty D, Cowan B, Shapiro J, Haegert A, Bell RH, Warshawski L, Carr N, Mc-Elwee KJ: Superficial, nodular, and morpheiform basal-cell carcinomas exhibit distinct gene expression profiles. J Invest Dermatol 2008; 128:1797-1805.
121. Serewko MM, Popa C, Dahler AL, Smith L, Strutton GM, Coman W, Dicker AJ, Saunders NA: Alterations in gene expression and activity during squamous cell carcinoma development. Cancer Res 2002;62: 3759-3765.
122. Dang C, Gottschling M, Manning K, O'Currain E, Schneider S, Sterry W, Stock-fleth E, Nindl I: Identification of dysregulated genes in cutaneous squamous cell carcinoma. Oncol Rep 2006; 16:513-519.
123. Nindl I, Dang C, Forschner T, Kuban RJ, Meyer T, Ster r y W, Stock f let h E: Identification of differentially expressed genes in cutaneous squamous cell carcinoma by microarray expression profiling. Mol Cancer 2006;5:30.
124. Dazard JE, Gal H, Amariglio N, Rechavi G, Domany E, Givol D: Genome-wide comparison of human keratinocyte and squamous cell carcinoma responses to UVB irradiation: implications for skin and epithelial cancer. Oncogene 2003; 22:2993-3006.
125. Slack JM: Conrad Hal Waddington: the last Renaissance biologist? Nat Rev Genet 2002; 3:889-895.
126. Rothhammer T, Bosserhoff AK: Epigenetic events in malignant melanoma. Pigment Cell Res 2007;20:92-111.
127. Jones PA, Baylin SB: The epigenomics of cancer. Cell 2007; 128:683-692.
128. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, Fry B, Meissner A, Wer nig M, Plath K, Jaenisch R, Wagschal A, Feil R, Schreiber SL, Lander ES: A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006; 125:315-326.
129. Bernstein BE, Meissner A, Lander ES: The mammalian epigenome. Cell 2007; 128:669-681.
130. Surani MA, Hayashi K, Hajkova P: Genetic and epigenetic regulators of pluripotency. Cell 2007; 128:747-762 .
131. Jiang SW, Li J, Podratz K, Dowdy S:Application of DNA methylation biomarkers for endometrial cancer management. Expert Rev Mol Diagn 2008;8:607-616.
132. Fraga MF, Esteller M: Epigenetics and aging:the targets and the marks. Trends Genet 2007;23:413-418.
133. Esteller M: The necessity of a human epigenome project. Carcinogenesis 2006;27: 1121-1125.
134. Feinberg AP, Ohlsson R, Henikoff S: The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006;7:21-33.
135. Laird PW:Cancer epigenetics. Hum Mol Genet 2005; 14:R65-R76.
136. Ting AH, McGarvey KM, Baylin SB: The cancer epigenome - components and functional correlates. Genes Dev 2006;20:3215-3231.
137. Li B, Carey M, Workman JL:The role of chromatin during transcription. Cell 2007; 128:707-719.
138. Baylin SB, Ohm JE:Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6:107-116.
139. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-428.
140. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007; 104:973-978.
141. Bennett DC: How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res 2008; 21:27-38.
142. Houben R, Wischhusen J, Menaa F, Syn-woldt P, Schrama D, Brocker EB, Becker JC: Melanoma stem cells: targets for successful therapy? J Dtsch Dermatol Ges 2008;6:541-546.
143. Esteller M: Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol 2005;45:629-656.
144. Nakamura M, Watanabe T, Klangby U, Asker C, Wiman K, Yonekawa Y, Kleihues P, Ohgaki H: p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 2001; 11:159-168.
145. Brown VL, Harwood CA, Crook T, Cronin JG, Kelsell DP, Proby CM:p16INK4a and p14ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma. J Invest Dermatol 2004;122: 1284-1292.
146. Xing EP, Nie Y, Song Y, Yang GY, Cai YC, Wang LD, Yang CS: Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res 1999;5:2704-2713.
147. Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB, Herman JG:Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 2000;60:129-133.
148. Murao K, Kubo Y, Ohtani N, Hara E, Arase S:Epigenetic abnormalities in cutaneous squamous cell carcinomas:frequent inactivation of the RB1/p16 and p53 pathways. Br J Dermatol 2006;155:999-1005.
149. Chiles MC, Ai L, Zuo C, Fan CY, Smoller BR: E-cadherin promoter hypermethylation in preneoplastic and neoplastic skin lesions. Mod Pathol 2003;16:1014-1018.
150. Sathyanarayana UG, Moore AY, Li L, Padar A, Majmudar K, Stastny V, Makarla P, Suzuki M, Minna JD, Feng Z, Gazdar AF: Sun exposure related methylation in malignant and non-malignant skin lesions. Cancer Lett 2007;245:112-120.
151. Dobrowolski R, Hein R, Buettner R, Bosserhoff AK: Loss of p14ARF expression in melanoma. Arch Dermatol Res 2002;293:545-551.
152. Straume O, Smeds J, Kumar R, Hemminki K, Akslen LA: Significant impact of promoter hypermethylation and the 540 C >T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am J Pathol 2002;16 1:229-237.
153. van der Velden PA, Metzelaar-Blok JA, Bergman W, Monique H, Hurks H, Frants RR, Gruis NA, Jager MJ: Promoter hypermethylation:a common cause of reduced p16(INK4a) expression in uveal melanoma. Cancer Res 2001;61:5303-5306.
154. Behrmann I, Wallner S, Komyod W, Heinrich PC, Schuierer M, Buettner R, Bosserhoff AK: Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma. Am J Pathol 2003; 163:683-690.
155. Niedojadlo K, Labedzka K, Lada E, Milewska A, Chwirot BW:Apaf-1 expression in human cutaneous melanoma progression and in pigmented nevi. Pigment Cell Res 2006; 9:43-50.
156. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C, Lowe SW:Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001;409:207-211.
157. Paz MF, Fraga MF, Avila S, Guo M, Pollan M, Herman JG, Esteller M:A systematic profile of DNA methylation in human cancer cell lines. Cancer Res 2003;63:1114-1121.
158. Poser I, Dominguez D, de Herreros AG, Varnai A, Buettner R, Bosserhoff AK: Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repressor Snail. J Biol Chem 2001; 276:24661-24666.
159. Tsutsumida A, Hamada J, Tada M, Aoyama T, Furuuchi K, Kawai Y, Yamamoto Y, Sugihara T, Moriuchi T: Epigenetic silencing of E- and P-cadherin gene expression in human melanoma cell lines. Int J Oncol 2004; 25:1415-1421.
160. Wilson AS, Power BE, Molloy PL: DNA hypomethylation and human diseases. Biochim Biophys Acta 2007;1775:138-162.
161. van Doorn R, Gruis NA, Willemze R, van der Velden PA, Tensen CP:Aberrant DNA methylation in cutaneous malignancies. Semin Oncol 2005;32:479-487.
162. Becker FF, Holton P, Ruchirawat M, Lapeyre JN: Perturbation of maintenance and de novo DNA methylation in vitro by UVB (280-340 nm)-induced pyrimidine photodimers. Proc Natl Acad Sci USA 1985;82: 6055-6059.
163. Ramanathan B, Smerdon MJ: Enhanced DNA repair synthesis in hyperacetylated nucleosomes. J Biol Chem 1989;264:11026 -11034.
164. Yu Y, Teng Y, Liu H, Reed SH, Waters R:U V irradiation stimulates histone acetylation and chromatin remodeling at a repressed yeast locus. Proc Natl Acad Sci USA 2005; 102:8650-8655.
165. Waters R, Reed SH, Yu Y, Teng Y: Chromatin modifications and nucleotide excision repair. SEB Exp Biol Ser 2008;59:189-201.
166. Mittal A, Piyathilake C, Hara Y, Katiyar SK:Exceptionally high protection of photo-carcinogenesis by topical application of (-)-epigallocatechin-3- gallate in hydrophilic cream in SKH-1 hairless mouse model: relationship to inhibition of UVB-induced global DNA hypomethylation. Neoplasia 2003;5:555-565.
167. Fornace AJ Jr, Nebert DW, Hollander MC, Luethy JD, Papathanasiou M, Fargnoli J, Holbrook NJ: Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents. Mol Cell Biol 1989;9:4196-4203.
168. Liebermann DA, Hoffman B: Gadd45 in stress signaling. J Mol Signal 2008;3:15.
169. Ying J, Srivastava G, Hsieh WS, Gao Z, Murray P, Liao SK, Ambinder R, Tao Q: The stress-responsive gene GADD45G is a functional tumor suppressor, with its response to environmental stresses frequently disrupted epigenetically in multiple tumors. Clin Cancer Res 2005; 11:6442-6449.
170. Mortusewicz O, Schermelleh L, Walter J, Cardoso MC, Leonhardt H: Recruitment of DNA methyltransferase I to DNA repair sites. Proc Natl Acad Sci USA 2005;102: 8905-8909.
171. Hoeijmakers JH: Genome maintenance mechanisms for preventing cancer. Nature 2001;411:366-374.
172. Melnikova VO, Ananthaswamy HN: Cellular and molecular events leading to the development of skin cancer. Mutat Res 2005; 571:91-106.
173. Rass K, Reichrath J:UV damage and DNA repair in malignant melanoma and nonmelanoma skin cancer. Adv Exp Med Biol 2008;624:162-178.
174. Chan TA, Glockner S, Yi JM, Chen W, Van Neste L, Cope L, Herman JG, Velculescu V, Schuebel KE, Ahuja N, Baylin SB: Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med 2008;5:e114.